Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-15 Sale | 2024-03-19 2:30 pm | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 50,000 | $6 | $300,000 | 984,476 (Direct) | View |
| 2024-03-08 Sale | 2024-03-12 1:45 pm | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 25,000 | $5.1874 | $129,685 | 1,034,476 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-09 Tax Withholding | 2024-03-12 1:47 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Barber Daniel President and CEO | 37,938 | $4.88 | 845,364 (Direct) | View |
| 2024-03-09 Tax Withholding | 2024-03-12 1:47 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Boyd Peter E. See Remark | 8,370 | $4.88 | 237,628 (Direct) | View |
| 2024-03-09 Tax Withholding | 2024-03-12 1:47 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | BRAENDER LORI J SVP, General Counsel | 10,530 | $4.88 | 313,231 (Direct) | View |
| 2024-03-09 Tax Withholding | 2024-03-12 1:47 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | TOTH A ERNEST JR SVP, Chief Financial Officer | 11,705 | $4.88 | 248,295 (Direct) | View |
| 2024-03-09 Tax Withholding | 2024-03-12 1:46 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development | 12,956 | $4.88 | 257,963 (Direct) | View |
| 2024-03-09 Tax Withholding | 2024-03-12 1:46 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations | 9,432 | $4.88 | 239,798 (Direct) | View |
| 2024-03-09 Tax Withholding | 2024-03-12 1:45 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 5,895 | $4.88 | 1,034,476 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:36 am | N/A 2034-03-07 | Aquestive Therapeutics Inc. | AQST | BRAENDER LORI J SVP, General Counsel | 202,500 | $0 | 391,261 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:36 am | N/A 2034-03-07 | Aquestive Therapeutics Inc. | AQST | TOTH A ERNEST JR SVP, Chief Financial Officer | 180,000 | $0 | 320,000 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:36 am | N/A 2034-03-07 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 123,750 | $0 | 1,106,621 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:35 am | N/A 2034-03-07 | Aquestive Therapeutics Inc. | AQST | Kraus Carl N Chief Medical Officer | 168,750 | $0 | 318,750 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:35 am | N/A 2034-03-07 | Aquestive Therapeutics Inc. | AQST | Barber Daniel President and CEO | 606,500 | $0 | 1,247,202 (Direct) | View |
| 2023-03-10 Tax Withholding | 2024-03-11 10:35 am | N/A N/A | Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations | 1,365 | $0 | 299,855 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:35 am | N/A 2024-03-07 | Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations | 151,875 | $0 | 299,855 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:35 am | N/A 2034-03-07 | Aquestive Therapeutics Inc. | AQST | Boyd Peter E. See Remark | 129,375 | $0 | 289,123 (Direct) | View |
| 2023-03-10 Tax Withholding | 2024-03-11 10:34 am | N/A N/A | Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development | 1,981 | $0.7937 | 327,169 (Direct) | View |
| 2024-03-07 Option Award | 2024-03-11 10:34 am | N/A 2034-03-07 | Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development | 168,750 | $0 | 327,169 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | BRAENDER LORI J SVP, General Counsel | 75,000 | $0 | 75,000 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Barber Daniel President and CEO | 223,500 | $0 | 223,500 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Boyd Peter E. See Remark | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 75,000 | $0 | 75,000 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Kraus Carl N Chief Medical Officer | 150,000 | $0 | 150,000 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development | 67,500 | $0 | 67,500 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | TOTH A ERNEST JR SVP, Chief Financial Officer | 70,000 | $0 | 70,000 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations | 55,000 | $0 | 55,000 (Direct) | View |
Ownership | 2023-06-30 4:06 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Kraus Carl N CHIEF MEDICAL OFFICER | 0 | $0 | 0 (Direct) | View |
| 2023-06-21 Option Award | 2023-06-23 1:41 pm | 2024-06-21 2033-06-21 | Aquestive Therapeutics Inc. | AQST | BROWN GREGORY B Director | 25,000 | $0 | 100,085 (Direct) | View |
| 2023-06-21 Option Award | 2023-06-23 12:28 pm | 2024-06-21 2033-06-21 | Aquestive Therapeutics Inc. | AQST | Krop Julie Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-06-21 Option Award | 2023-06-23 12:27 pm | 2024-06-21 2033-06-21 | Aquestive Therapeutics Inc. | AQST | MORRIS TIMOTHY E Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-06-21 Option Award | 2023-06-23 12:26 pm | 2024-06-21 2033-06-21 | Aquestive Therapeutics Inc. | AQST | Taglietti Marco Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-06-21 Option Award | 2023-06-23 12:26 pm | 2024-06-21 2033-06-21 | Aquestive Therapeutics Inc. | AQST | COSTA SANTO J Director | 25,000 | $0 | 42,327 (Direct) | View |
| 2023-06-21 Option Award | 2023-06-23 12:24 pm | 2024-06-21 2033-06-21 | Aquestive Therapeutics Inc. | AQST | Cochran John Director | 25,000 | $0 | 124,486 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Wargacki Stephen SVP, Research & Development | 67,500 | $0 | 67,500 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | TOTH A ERNEST JR SVP, Chief Financial Officer | 70,000 | $0 | 70,000 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | BRAENDER LORI J SVP, General Counsel | 75,000 | $0 | 75,000 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Barber Daniel President and CEO | 223,500 | $0 | 223,500 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 75,000 | $0 | 75,000 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Jung Cassie SVP, Operations | 55,000 | $0 | 55,000 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Boyd Peter E. See Remark | 50,000 | $0 | 50,000 (Direct) | View |